A detailed history of Nisa Investment Advisors, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 3,465 shares of RNA stock, worth $150,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,465
Previous 4,399 21.23%
Holding current value
$150,138
Previous $179,000 11.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$37.21 - $48.14 $34,754 - $44,962
-934 Reduced 21.23%
3,465 $159,000
Q2 2024

Jul 19, 2024

BUY
$22.73 - $40.85 $24,457 - $43,954
1,076 Added 32.38%
4,399 $179,000
Q1 2024

May 01, 2024

BUY
$9.16 - $25.52 $1,126 - $3,138
123 Added 3.84%
3,323 $84,000
Q4 2023

Jan 25, 2024

BUY
$4.87 - $9.37 $15,486 - $29,796
3,180 Added 15900.0%
3,200 $28,000
Q3 2023

Nov 02, 2023

SELL
$6.3 - $11.35 $11,831 - $21,315
-1,878 Reduced 98.95%
20 $0
Q2 2023

Aug 11, 2023

BUY
$10.62 - $17.34 $10,237 - $16,715
964 Added 103.21%
1,898 $21,000
Q1 2023

May 02, 2023

BUY
$15.35 - $25.65 $13,968 - $23,341
910 Added 3791.67%
934 $14,000
Q4 2022

Feb 02, 2023

SELL
$10.06 - $22.66 $261 - $589
-26 Reduced 52.0%
24 $1,000
Q3 2022

Nov 07, 2022

SELL
$15.46 - $23.43 $2,906 - $4,404
-188 Reduced 78.99%
50 $1,000
Q1 2022

Apr 29, 2022

SELL
$14.2 - $23.78 $27,264 - $45,657
-1,920 Reduced 88.97%
238 $4,000
Q4 2021

Feb 03, 2022

BUY
$20.4 - $28.66 $32,456 - $45,598
1,591 Added 280.6%
2,158 $36,000
Q3 2021

Oct 18, 2021

SELL
$18.16 - $25.21 $83,536 - $115,966
-4,600 Reduced 89.03%
567 $14,000
Q4 2020

Jan 25, 2021

BUY
$24.73 - $35.12 $127,779 - $181,465
5,167 New
5,167 $132,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.26B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.